JP2020521726A5 - - Google Patents

Download PDF

Info

Publication number
JP2020521726A5
JP2020521726A5 JP2019559117A JP2019559117A JP2020521726A5 JP 2020521726 A5 JP2020521726 A5 JP 2020521726A5 JP 2019559117 A JP2019559117 A JP 2019559117A JP 2019559117 A JP2019559117 A JP 2019559117A JP 2020521726 A5 JP2020521726 A5 JP 2020521726A5
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
achieves
dosage form
daily dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019559117A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020521726A (ja
JP7293129B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2018/020643 external-priority patent/WO2018221546A1/en
Publication of JP2020521726A publication Critical patent/JP2020521726A/ja
Publication of JP2020521726A5 publication Critical patent/JP2020521726A5/ja
Application granted granted Critical
Publication of JP7293129B2 publication Critical patent/JP7293129B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019559117A 2017-06-01 2018-05-30 Pde9阻害剤を含む医薬組成物 Active JP7293129B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762513690P 2017-06-01 2017-06-01
US62/513,690 2017-06-01
PCT/JP2018/020643 WO2018221546A1 (en) 2017-06-01 2018-05-30 Pharmaceutical composition comprising pde9 inhibitor

Publications (3)

Publication Number Publication Date
JP2020521726A JP2020521726A (ja) 2020-07-27
JP2020521726A5 true JP2020521726A5 (cg-RX-API-DMAC7.html) 2021-07-26
JP7293129B2 JP7293129B2 (ja) 2023-06-19

Family

ID=64455959

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019559117A Active JP7293129B2 (ja) 2017-06-01 2018-05-30 Pde9阻害剤を含む医薬組成物

Country Status (12)

Country Link
US (2) US11484502B2 (cg-RX-API-DMAC7.html)
EP (1) EP3630113A4 (cg-RX-API-DMAC7.html)
JP (1) JP7293129B2 (cg-RX-API-DMAC7.html)
KR (1) KR20200010211A (cg-RX-API-DMAC7.html)
CN (2) CN116585316A (cg-RX-API-DMAC7.html)
AU (1) AU2018276566A1 (cg-RX-API-DMAC7.html)
BR (1) BR112019023557A2 (cg-RX-API-DMAC7.html)
CA (1) CA3059539A1 (cg-RX-API-DMAC7.html)
MX (1) MX2019013198A (cg-RX-API-DMAC7.html)
RU (1) RU2019135261A (cg-RX-API-DMAC7.html)
SG (1) SG11201909359YA (cg-RX-API-DMAC7.html)
WO (1) WO2018221546A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200010220A (ko) 2017-06-01 2020-01-30 에자이 알앤드디 매니지먼트 가부시키가이샤 피라졸로퀴놀린 유도체를 함유하는 루이소체 질병 치료제
BR112019023569A2 (pt) 2017-06-01 2020-06-02 Eisai R&D Management Co., Ltd. Agente terapêutico da demência combinando derivados de pirazoloquinolina e donepezila
JP7177772B2 (ja) 2017-06-01 2022-11-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピラゾロキノリン誘導体とメマンチンの併用による認知症治療剤
KR20240101561A (ko) 2021-10-14 2024-07-02 인사이트 코포레이션 Kras의 저해제로서의 퀴놀린 화합물
WO2024107445A1 (en) * 2022-11-15 2024-05-23 Freedom Biosciences, Inc. Enhancement of the efficacy of serotonergic psychedelic drugs in the treatment or prevention of certain neuropsychiatric disorders through inhibition of type-9 phosphodiesterases
CN119302958B (zh) * 2023-12-01 2025-10-21 郑州大学第一附属医院 含有bay 73-6691或其衍生物的药物制剂在制备治疗脑损伤疾病药物中的应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5318759A (en) 1976-08-02 1978-02-21 Nisshin Oil Mills Ltd Method of making fried beancurd
JPH05132484A (ja) 1991-04-26 1993-05-28 Otsuka Pharmaceut Factory Inc ピラゾロキノリン及びピラゾロナフチリジン誘導体
DE69518075T2 (de) 1994-05-24 2001-03-22 F. Hoffmann-La Roche Ag, Basel Tricyclische dicarbonylderivate
DE19642591A1 (de) 1996-10-15 1998-04-16 Basf Ag Neue Piperidin-Ketocarbonsäure-Derivate, deren Herstellung und Anwendung
HN2002000317A (es) 2001-11-02 2003-05-21 Pfizer Inhibidores de pde9 para tratamiento de trastornos cardiovasculares
EP1537106A1 (en) 2002-08-07 2005-06-08 Mitsubishi Pharma Corporation Dihydropyrazolopyridine compounds
DE10238722A1 (de) * 2002-08-23 2004-03-11 Bayer Ag Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
DE102004004142A1 (de) 2003-05-09 2004-11-25 Bayer Healthcare Ag 6-Cyclylmethyl- und 6-Alkylmethyl-substituierte Pyrazolopyrimidine
RU2426734C2 (ru) 2003-10-03 2011-08-20 Зм Инновейтив Пропертиз Компани Пиразолопиридины и их аналоги
US20060035920A1 (en) 2004-05-28 2006-02-16 Millennium Pharmaceuticals, Inc. Chk-1 inhibitors
JP2006045118A (ja) 2004-08-04 2006-02-16 Mochida Pharmaceut Co Ltd 新規ピラゾロキノロン誘導体
WO2007032466A1 (ja) 2005-09-15 2007-03-22 Aska Pharmaceutical Co., Ltd. 複素環化合物、その製造方法並びに用途
TW200808741A (en) 2006-06-09 2008-02-16 Wyeth Corp 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline hydrochloric acid salts
WO2007146073A2 (en) 2006-06-09 2007-12-21 Wyeth Method for enhancing cognitive function
WO2008072779A1 (ja) 2006-12-13 2008-06-19 Aska Pharmaceutical Co., Ltd. キノキサリン誘導体
AU2007332439A1 (en) 2006-12-13 2008-06-19 Aska Pharmaceutical Co., Ltd. Therapeutic agent for urinary tract disease
PT2152712E (pt) 2007-05-11 2012-02-29 Pfizer Compostos amino-heterocíclicos
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
CN102143965A (zh) 2008-09-08 2011-08-03 贝林格尔.英格海姆国际有限公司 吡唑并嘧啶酮及其在治疗中枢神经系统疾病中的用途
TWI404721B (zh) 2009-01-26 2013-08-11 Pfizer 胺基-雜環化合物
AU2010219598A1 (en) 2009-03-05 2011-09-22 Astellas Pharma Inc. Quinoxaline compounds
UY32531A (es) 2009-03-31 2010-10-29 Boehringer Ingelheim Int Nuevos compuestos para el tratamiento de trastornos del snc
LT2419104T (lt) 2009-04-13 2018-02-12 Theravance Biopharma R&D Ip, Llc 5-ht4 receptoriaus agonistų ir acetilcholinesterazės inhibitorių deriniai, skirti pažinimo sutrikimų gydymui
US8880976B2 (en) 2009-09-25 2014-11-04 Stmicroelectronics, Inc. Method and apparatus for encoding LBA information into the parity of a LDPC system
BR112013003097B1 (pt) 2010-08-12 2021-03-16 Boehringer Ingelheim International Gmbh 6-cicloalquil-pirazolopirimidinonas e composição farmacêutica
ES2583528T3 (es) 2010-09-07 2016-09-21 Astellas Pharma Inc. Compuesto de pirazoloquinolina
US20130040971A1 (en) 2011-02-14 2013-02-14 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of cns disorders
JP6042060B2 (ja) 2011-09-26 2016-12-14 サノフイ ピラゾロキノリノン誘導体、その調製および治療上の使用
SI2573073T1 (sl) 2011-09-26 2015-02-27 Sanofi Pirazolokinolinonski derivati, njihova priprava in njihova terapevtska uporaba
JP5938299B2 (ja) 2011-10-05 2016-06-22 ダイセルポリマー株式会社 繊維強化樹脂組成物
CN103930423B (zh) * 2011-10-07 2015-09-16 卫材Rd管理有限公司 吡唑并喹啉衍生物
JP5666755B1 (ja) 2013-04-05 2015-02-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピラゾロキノリン誘導体の塩およびその結晶
WO2016179569A1 (en) 2015-05-07 2016-11-10 Axovant Sciences Ltd. Compositions and methods of treating a neurodegenerative disease
KR20200010220A (ko) 2017-06-01 2020-01-30 에자이 알앤드디 매니지먼트 가부시키가이샤 피라졸로퀴놀린 유도체를 함유하는 루이소체 질병 치료제
JP7177772B2 (ja) 2017-06-01 2022-11-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピラゾロキノリン誘導体とメマンチンの併用による認知症治療剤
BR112019023569A2 (pt) 2017-06-01 2020-06-02 Eisai R&D Management Co., Ltd. Agente terapêutico da demência combinando derivados de pirazoloquinolina e donepezila

Similar Documents

Publication Publication Date Title
AU2016226006B2 (en) Method of treatment with tradipitant
CN109890391B (zh) 痴呆症的治疗
JP2014517050A5 (cg-RX-API-DMAC7.html)
JP2022110143A5 (cg-RX-API-DMAC7.html)
JP2013501731A5 (cg-RX-API-DMAC7.html)
JP2017506624A5 (cg-RX-API-DMAC7.html)
IL270395B (en) Dementia therapeutic agent combining pyrazoloquinoline derivative and donepezil
FI3856341T3 (fi) (s)-1-(4-fluorifenyyli)-1-(2-(4-(6-(1-metyyli-1h-pyratsol-4-yyli)pyrrolo[2,1-f][1,2,4]triatsin-4-yyli)piperatsinyyli)pyrimidin-5-yyli)etaani-1-amiinin kidemuotoja ja valmistusmenetelmiä
JP2020521797A5 (cg-RX-API-DMAC7.html)
RU2019135261A (ru) Фармацевтическая композиция, содержащая ингибитор pde9
JP5738397B2 (ja) 帯状ヘルペス疾患の治療用のオピオイド受容体拮抗薬(ナルトレキソン)
CN110603039B (zh) 组合吡唑并喹啉衍生物和美金刚的痴呆治疗剂
JP2014513705A (ja) 進行性固形腫瘍の治療方法
EP4520394A3 (en) New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases
JP2011518168A5 (cg-RX-API-DMAC7.html)
JP2014517078A5 (cg-RX-API-DMAC7.html)
JP2015516980A5 (cg-RX-API-DMAC7.html)
JP2021167361A (ja) 神経変性障害を処置するための方法
JP2022514561A5 (cg-RX-API-DMAC7.html)
US20060148802A1 (en) Use of compounds that stimulate cgmp
WO2010110428A1 (ja) 掻痒の予防及び/または治療剤
FI3909568T3 (fi) Profylaktinen tai terapeuttinen lääke neurodegeneratiivisiin tauteihin
JP2503571B2 (ja) 脳循環代謝改善剤
JP2021091608A5 (cg-RX-API-DMAC7.html)
IL273543B1 (en) New treatment of sma